Neuronal Life Span Versus Health Span: Principles of Natural Selection at Work in the Degenerating Brain

  • John C. O’LearyIII
  • John KorenIII
  • Chad A. Dickey


Impaired nutrient delivery to the brain due to decreased blood flow contributes to cognitive decline and dementia in Alzheimer’s disease (AD). Considering this, many studies have suggested that neuroprotective agents like those used in stroke could prevent AD onset or progression by promoting cell survival. However, research in the past decade suggests that the culprit behind the cognitive loss in AD models is actually the soluble tau accumulating inside of surviving neurons. In fact, tau reductions improve cognition in mouse models of AD, even those that only deposit amyloid plaques. There is emerging evidence that neuroprotection alone in these AD models may be insufficient to restore neuron function and cognition. Only when soluble tau is reduced on a neuroprotective background could memory be rescued. Thus, once a neuron begins to accumulate tau, it may survive in a malfunctioning capacity, leading to impaired electrical signaling and memory formation in the brain. These data imply that multiple drugs may be necessary to ameliorate the different disease components. In fact, strategies to preserve neurons without affecting the soluble protein burden within neurons may accelerate the disease course.


Tau Alzheimer’s Neurodegeneration Neuroprotection Solubility 


  1. Abisambra JF, Blair LJ, Hill SE et al (2010) Phosphorylation dynamics regulate Hsp27-mediated rescue of neuronal plasticity deficits in tau transgenic mice. J Neurosci 30:15374–15382PubMedCrossRefGoogle Scholar
  2. Albani D, Polito L, Signorini A, Forloni G (2010) Neuroprotective properties of resveratrol in different neurodegenerative disorders. Biofactors 36:370–376PubMedCrossRefGoogle Scholar
  3. Andorfer C, Kress Y, Espinoza M et al (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86:582–590PubMedCrossRefGoogle Scholar
  4. Bell RD, Deane R, Chow N et al (2009) SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol 11:143–153PubMedCrossRefGoogle Scholar
  5. Brewer GJ (2010) Why vitamin E therapy fails for treatment of Alzheimer’s disease. J Alzheimers Dis 19:27–30PubMedGoogle Scholar
  6. Chow N, Bell RD, Deane R et al (2007) Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer’s phenotype. Proc Natl Acad Sci USA 104:823–828PubMedCrossRefGoogle Scholar
  7. Dayanandan R, Van Slegtenhorst M, Mack TG et al (1999) Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett 446:228–232PubMedCrossRefGoogle Scholar
  8. de Calignon A, Fox LM, Pitstick R et al (2010) Caspase activation precedes and leads to tangles. Nature 26:787–789Google Scholar
  9. Ghiso J, Matsubara E, Koudinov A et al (1993) The cerebrospinal-fluid soluble form of Alzheimer’s amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane–attack complex. Biochem J 293(Pt 1):27–30PubMedGoogle Scholar
  10. Grundman M (2000) Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 71:630S–636SPubMedGoogle Scholar
  11. Harada A, Oguchi K, Okabe S et al (1994) Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369:488–491PubMedCrossRefGoogle Scholar
  12. Hwang IK, Yoo KY, Li H et al (2009) Indole-3-propionic acid attenuates neuronal damage and oxidative stress in the ischemic hippocampus. J Neurosci Res 87:2126–2137PubMedCrossRefGoogle Scholar
  13. Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci 5:347–360PubMedCrossRefGoogle Scholar
  14. Ittner LM, Ke YD, Delerue F et al (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 142:387–397PubMedCrossRefGoogle Scholar
  15. Jinwal UK, Miyata Y, Koren J 3rd et al (2009) Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci 29:12079–12088PubMedCrossRefGoogle Scholar
  16. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int 54:111–118PubMedCrossRefGoogle Scholar
  17. Kim D, Nguyen MD, Dobbin MM et al (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J 26:3169–3179PubMedCrossRefGoogle Scholar
  18. Kimura T, Fukuda T, Sahara N et al (2010) Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J Biol Chem 285:38692–38699PubMedCrossRefGoogle Scholar
  19. King ME, Kan HM, Baas PW, Erisir A, Glabe CG, Bloom GS (2006) Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol 175:541–546PubMedCrossRefGoogle Scholar
  20. Matsubara E, Ghiso J, Frangione B et al (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer’s disease and Down’s syndrome. Ann Neurol 45:537–541PubMedCrossRefGoogle Scholar
  21. Medina DX, Caccamo A, Oddo S (2011) Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 21(2):140–149PubMedCrossRefGoogle Scholar
  22. Morshedi D, Rezaei-Ghaleh N, Ebrahim-Habibi A, Ahmadian S, Nemat-Gorgani M (2007) Inhibition of amyloid fibrillation of lysozyme by indole derivatives—possible mechanism of action. FEBS J 274:6415–6425PubMedGoogle Scholar
  23. Niwa K, Younkin L, Ebeling C et al (2000) Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci USA 97:9735–9740PubMedCrossRefGoogle Scholar
  24. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C (2001) A beta-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 281:H2417–H2424PubMedGoogle Scholar
  25. O’Connor T, Sadleir KR, Maus E et al (2008) Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 60:988–1009PubMedCrossRefGoogle Scholar
  26. O’Leary JC 3rd, Li Q, Marinec P et al (2010) Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener 5:45PubMedCrossRefGoogle Scholar
  27. Paris D, Townsend KP, Humphrey J, Obregon DF, Yokota K, Mullan M (2002) Statins inhibit A beta-neurotoxicity in vitro and A beta-induced vasoconstriction and inflammation in rat aortae. Atherosclerosis 161:293–299PubMedCrossRefGoogle Scholar
  28. Petersen RC, Thomas RG, Grundman M et al (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352:2379–2388PubMedCrossRefGoogle Scholar
  29. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A (2002) Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 99:6364–6369PubMedCrossRefGoogle Scholar
  30. Redwine JM, Kosofsky B, Jacobs RE et al (2003) Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc Natl Acad Sci USA 100:1381–1386PubMedCrossRefGoogle Scholar
  31. Roberson ED, Scearce-Levie K, Palop JJ et al (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science 316:750–754PubMedCrossRefGoogle Scholar
  32. Santacruz K, Lewis J, Spires T et al (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476–481PubMedCrossRefGoogle Scholar
  33. Schwarzman AL, Gregori L, Vitek MP et al (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA 91:8368–8372PubMedCrossRefGoogle Scholar
  34. Shibata M, Yamada S, Kumar SR et al (2000) Clearance of Alzheimer’s amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier. J Clin Invest 106:1489–1499PubMedCrossRefGoogle Scholar
  35. Simon-Sanchez J, Schulte C, Bras JM et al (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41:1308–1312PubMedCrossRefGoogle Scholar
  36. Tucker KL, Meyer M, Barde YA (2001) Neurotrophins are required for nerve growth during development. Nat Neurosci 4:29–37PubMedCrossRefGoogle Scholar
  37. Urmoneit B, Prikulis I, Wihl G et al (1997) Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab Invest 77:157–166PubMedGoogle Scholar
  38. Wagner U, Utton M, Gallo JM, Miller CC (1996) Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 109(Pt 6):1537–1543PubMedGoogle Scholar
  39. Wang J, Ho L, Zhao Z et al (2006) Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer’s disease. FASEB J 20:2313–2320PubMedCrossRefGoogle Scholar
  40. Wischik C, Staff R (2009) Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Health Aging 13:367–369PubMedCrossRefGoogle Scholar
  41. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 93:11213–11218PubMedCrossRefGoogle Scholar
  42. Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN (1997) Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J Neurochem 68:721–725PubMedCrossRefGoogle Scholar
  43. Yuan A, Kumar A, Peterhoff C, Duff K, Nixon RA (2008) Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J Neurosci 28:1682–1687PubMedCrossRefGoogle Scholar
  44. Zlokovic BV (2008) The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178–201PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • John C. O’LearyIII
    • 1
  • John KorenIII
    • 1
  • Chad A. Dickey
    • 1
    • 2
  1. 1.USF Health Byrd Alzheimer’s InstituteTampaUSA
  2. 2.Department of Molecular Medicine, USF Health Byrd Alzheimer’s InstituteUniversity of South FloridaTampaUSA

Personalised recommendations